Matinas BioPharma (NYSE:MTNB) Holdings, Inc. (NYSE American:MTNB), a pharmaceutical company specializing in the development of drug delivery technologies with a current market capitalization of $3 ...

Matinas BioPharma (MTND) filed a prospectus for the offer and sale of 16.89M shares of common stock by the selling stockholders. This preliminary prospectus is not an offer to sell these securities.

In a recent Special Meeting held on Monday, Matinas BioPharma (NYSE:MTNB) Holdings, Inc. received shareholder approval on several significant proposals. The meeting, which was convened on April 4 ...

Matinas BioPharma's gross profit margin for fiscal years ending December 2019 to 2023 averaged -13,422.8%. Matinas BioPharma's operated at median gross profit margin of -8,968.8% from fiscal years ...

Matinas BioPharma (NYSE:MTNB) Holdings, Inc. (NYSE American:MTNB), a pharmaceutical company with a market capitalization of $3.1 million and currently trading at $0.61 per share, announced on Monday ...

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

1 Day MTNB 12.61% DJIA 0.05% Russell 2K 0.00% Health Care/Life Sciences -0.16% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Matinas BioPharma's gross profit margin for fiscal years ending December 2019 to 2023 averaged -13,422.8%. Matinas BioPharma's operated at median gross profit margin of -8,968.8% from fiscal years ...